SVA
Sinovac Biotech Ltd
NASDAQ: SVA · HEALTHCARE · BIOTECHNOLOGY
$6.47
+0.00% today
Updated 2026-04-29
Market cap
$642.44M
P/E ratio
6.66
P/S ratio
1.83x
EPS (TTM)
$0.97
Dividend yield
850.00%
52W range
$6 – $6
Volume
—
WallStSmart proprietary scores
78
out of 100
Grade: B+
Buy
Investment rating
7.3
Growth
B+8.5
Quality
A9.0
Profitability
A+8.3
Valuation
A3/9
Piotroski F-Score
Weak
6.1
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$3.52
-45.60%
12-Month target
$8.08
+24.88%
Intrinsic (DCF)
$22.06
Margin of safety
+70.67%
Price chart
X-Ray snapshot
Strengths
+ Altman Z 6.08 — safe zone
+ Profit margin 21.60% — above average
+ ROE 25.20% — strong efficiency
+ Free cash flow $93.26M — positive
+ Revenue growth 303.70% QoQ
Risks
- Piotroski 3/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2020 | 2021 | 2022 | 2023 | TTM |
|---|---|---|---|---|---|
| Revenue | $510.62M | $19.37B | $1.49B | $448.27M | $510.62M |
| Net income | $110.37M | $8.47B | $113.87M | $-99.92M | $-116.84M |
| EPS | — | — | — | — | $0.97 |
| Free cash flow | $351.66M | $14.63B | $-1.17B | $-39.67M | $93.26M |
| Profit margin | 21.61% | 43.70% | 7.63% | -22.29% | 21.60% |
Peer comparison
Smart narrative
Sinovac Biotech Ltd trades at $6.47. representing a P/E of 6.66x trailing earnings. Our Smart Value Score of 78/100 indicates the stock is good. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 6.08, it sits in the safe zone. TTM revenue stands at $510.62M. with profit margins at 21.60%. Our DCF model estimates intrinsic value at $22.06.
Frequently asked questions
What is Sinovac Biotech Ltd's stock price?
Sinovac Biotech Ltd (SVA) trades at $6.47.
Is Sinovac Biotech Ltd overvalued?
Smart Value Score 78/100 (Grade B+, Buy). DCF value $22.06.
What is the price target of Sinovac Biotech Ltd (SVA)?
The analyst target price is $3.52, representing -45.6% downside from the current price of $6.47.
What is the intrinsic value of Sinovac Biotech Ltd (SVA)?
Based on our DCF model, intrinsic value is $22.06, a +70.7% margin of safety versus $6.47.
What is the future stock price of SVA by 2030?
Our revenue-driven model estimates Sinovac Biotech Ltd could reach $12.63 by 2030, based on historical CAGR, margin trends, and capped P/E multiples.
What is Sinovac Biotech Ltd's revenue?
TTM revenue is $510.62M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
6.08 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryChina
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.83x
ROE25.20%
Beta0.07
50D MA$6.47
200D MA$6.47
Shares out0.10B
Float0.06B
Short ratio—
Avg volume—
Performance
1 week+0.00%
1 month+0.00%
3 months+0.00%
YTD+0.00%
1 year—
3 years—
5 years—